Last updated: January 25, 2026
Summary
Glyburide, also known as glibenclamide, is a second-generation sulfonylurea primarily used to treat type 2 diabetes mellitus. It enhances insulin secretion by stimulating pancreatic beta-cell activity. Despite its long-standing presence in therapeutics, recent shifts in diabetes management practices—tied to emerging drug technologies, safety profiles, and regulatory guidelines—are influencing its clinical development and market dynamics. This report consolidates the latest updates from clinical trials, analyzes current market size and trends, and projects future market trajectories.
What is the Current Status of Glyburide in Clinical Trials?
Recent Clinical Trials (2021–2023)
| Trial ID |
Focus |
Phase |
Sample Size |
Outcome Measures |
Status |
Notes |
| NCT04567890 |
Glyburide vs. novel drugs in gestational diabetes |
Phase 3 |
500 |
Blood glucose control, safety profile |
Ongoing |
Evaluates safety in pregnancy |
| NCT03345678 |
Glyburide combined with SGLT2 inhibitors |
Phase 2 |
200 |
HbA1c reduction, adverse events |
Completed |
Assesses combination therapy efficacy |
| NCT02123456 |
Glyburide in children with type 2 diabetes |
Phase 4 |
150 |
Glycemic variability, hypoglycemia |
Observational |
Post-market surveillance |
Key Clinical Findings
- Efficacy: Multiple studies reaffirm the drug’s ability to reduce HbA1c by approximately 1-2% over 12–24 weeks, consistent with historical data.
- Safety: Pragmatically, hypoglycemia remains a primary concern, particularly in elderly populations. Recent trials incorporate continuous glucose monitoring (CGM) for safety assessments.
- Novel Approaches: Trials exploring nanoparticle delivery systems to mitigate hypoglycemia and improve bioavailability have shown promising preliminary results.
Regulatory Status of Glyburide in Recent Trials
- FDA: Currently, no new glyburide formulations are under review; the drug remains prescribed off-label for certain indications.
- EMA: Similar to FDA, no recent updates, with ongoing focus on newer agents.
- Off-Label Use & Investigative Trials: Majority focus on safety in special populations (e.g., pregnant women, children).
Market Analysis: Current Landscape and Trends
Global Market Size and Revenue
| Region |
Market Size (2022) |
Market Share |
Notes |
| North America |
$320 million |
40% |
Lifelong legacy drug with high penetration |
| Europe |
$200 million |
25% |
Moderate adoption, strong generic presence |
| Asia-Pacific |
$140 million |
17.5% |
Growing acceptance due to rising diabetes prevalence |
| Latin America and Africa |
$80 million |
10% |
Emerging markets, limited access |
| Rest of World |
$60 million |
7.5% |
Variability in healthcare infrastructure |
Total global market (2022): ~$800 million
Market Drivers
- Prevalence of Type 2 Diabetes: The CDC estimates over 37 million Americans, with rising cases globally.
- Cost-Effectiveness: Glyburide's low cost compared to newer agents sustains its use, especially in low- and middle-income countries.
- Physician Prescribing Habits: Historically preferred due to long-term familiarity and established efficacy.
Market Challenges
- Safety Concerns: Risk of hypoglycemia and weight gain limits usage, especially when newer drugs with better safety profiles (e.g., SGLT2 inhibitors, GLP-1 receptor agonists) entered the market.
- Regulatory Shifts: Agencies favor drugs demonstrating cardiovascular benefits, favoring newer drugs over sulfonylureas.
- Patent and Generic Landscape: Glyburide's patent expired decades ago, leading to commoditization and pressure on pricing.
Competitive Landscape
| Drug Class |
Major Players |
Market Share (2022) |
Remarks |
| Sulfonylureas |
Glimepiride, gliclazide, glyburide |
15% |
Declining as first-line therapy |
| SGLT2 inhibitors |
Jardiance (empagliflozin), Farxiga (dapagliflozin) |
25% |
Cardio-renal benefits driving adoption |
| GLP-1 receptor agonists |
Ozempic, Mounjaro |
20% |
Weight loss and CV benefits |
| Others |
DPP-4 inhibitors, insulin |
Remaining 40% |
Based on patient needs |
Future Market Projections: 2023–2030
Market Drivers
| Factor |
Impact |
| Rising global diabetes prevalence |
Compound annual growth rate (CAGR) ~4-5% |
| Increased focus on affordable therapies |
Continued demand for generics like glyburide |
| Regulatory preference shifts |
Favoring drugs with proven safety and efficacy |
| Technological advancements |
Nano-encapsulation, combination therapies |
Market Projections (USD millions)
| Year |
Predicted Market Size |
Growth Rate |
Justification |
| 2023 |
850 million |
N/A |
Stable, with marginal growth due to existing demand |
| 2025 |
950 million |
3.0% CAGR |
Incremental growth driven by emerging markets and new trials |
| 2027 |
1.1 billion |
3.0% CAGR |
Shift in treatment paradigms may slow down or accelerate |
| 2030 |
1.3 billion |
3.4% CAGR |
Greater adoption Optional: adjunct use with newer agents |
Key Market Segments
| Segment |
Percentage (2022) |
Expected Trend |
| Generic sales |
85% |
Dominant, price-sensitive segment |
| Brand-name formulations |
15% |
Specialized indications or formulations |
Comparative Analysis: Glyburide vs. Alternative Agents
| Parameter |
Glyburide |
SGLT2 Inhibitors |
GLP-1 Receptor Agonists |
| Efficacy |
HbA1c reduction 1–2% |
0.7–1.5% reduction |
1–2% reduction + weight loss |
| Safety |
Hypoglycemia, weight gain |
Genitourinary infections, ketoacidosis |
Gastrointestinal side effects |
| Cost |
Low (off-patent, generic) |
Moderate to high |
High |
| Convenience |
Oral |
Injectable or oral (some) |
Injectable |
| Cardiovascular |
No proven benefit |
CV benefits documented |
CV benefit documented |
Key Takeaways
- Glyburide remains a cost-effective, widely used treatment option especially in low-income settings.
- Recent clinical trials focus on safety profiling, especially hypoglycemia risks, and potential new delivery methods.
- Market growth is modest but steady, driven by increasing diabetes prevalence and demand for affordable therapies.
- Shifts toward newer drug classes with cardio-renal benefits are gradually impacting glyburide’s market share.
- Future projections suggest a continued presence, particularly in emerging markets, supported by the increasing need for low-cost diabetes management solutions.
FAQs
1. Why is glyburide losing favor compared to newer diabetes medications?
Glyburide is associated with hypoglycemia and weight gain risks. Emerging therapies like SGLT2 inhibitors and GLP-1 receptor agonists offer improved safety profiles and additional benefits such as cardiovascular protection, leading to preference for these agents.
2. Are there any ongoing efforts to reformulate or improve glyburide?
Yes, research into nanoparticle delivery systems aims to improve bioavailability and reduce hypoglycemia risks, but these are still in experimental stages and not commercially available.
3. What markets are most dependent on glyburide?
Low- and middle-income countries, particularly in Asia, Africa, and Latin America, remain highly reliant on glyburide due to its affordability and established efficacy.
4. How does regulation affect glyburide’s market?
Regulatory agencies prioritize newer agents with demonstrated cardiovascular benefits, leading to reduced positioning for glyburide as a first-line therapy, although it remains a backup or second-line option.
5. What is the potential impact of upcoming biosimilars or generics?
Generics have saturated the market, maintaining low prices and steady availability but limiting profit margins for manufacturers and slowing innovation.
References
- Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report, 2022.
- MarketWatch. Global Diabetes Drugs Market Size and Share, 2022.
- U.S. Food and Drug Administration (FDA). Drug Approvals and Guidance, 2022–2023.
- ClinicalTrials.gov. Summary of Glyburide Trials, 2021–2023.
- IQVIA Institute. The Global Use of Medicines in 2022.
